Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins

Spyre's three-pronged approach to inflammatory bowel disease continues to pay off, with the biotech's anti-IL-23 antibody notching a phase 2 win.